Imatinib Cipla

Imatinib, the active ingredient in Imatinib Cipla, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients, targeting abnormal cell signaling pathways that drive cancer growth.

GNH USA supplies Imatinib Cipla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib acts on malignant cells that depend on BCR‑ABL, c‑KIT or PDGFR signaling, making it a cornerstone therapy for several hematologic and solid tumours.

- Chronic Myeloid Leukemia (CML): reduces leukemic cell proliferation and improves long‑term survival. - Gastrointestinal Stromal Tumor (GIST): inhibits tumor growth and prolongs progression‑free survival. - Philadelphia‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): achieves molecular remission by targeting BCR‑ABL driven blasts.

Adverse reactions vary in frequency and severity. Monitoring and supportive care are essential during therapy.

Common Side Effects: - Nausea - Edema (peripheral fluid retention) - Muscle cramps or pain - Fatigue - Diarrhea - Rash or mild skin irritation

Serious or Rare Side Effects: - Hepatotoxicity (elevated liver enzymes, hepatitis) - Severe neutropenia or thrombocytopenia - Cardiac failure or reduced left‑ventricular function - Pulmonary arterial hypertension - Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly for emerging toxicities.

- Monitor blood counts: perform complete blood count at baseline and periodically. - Assess liver function: check hepatic enzymes before treatment and during therapy. - Evaluate cardiac status: perform echocardiogram if history of heart disease. - Avoid use in patients with known hypersensitivity to imatinib or its excipients. - Use caution in pregnancy and breastfeeding; discuss risks with the prescriber. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib metabolism involves CYP3A4, and co‑administered drugs can alter its plasma concentrations, requiring dose adjustments or close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Concomitant warfarin: increased anticoagulant effect and INR.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors or H2‑blockers: may modestly decrease absorption. - CYP2C8 inhibitors (e.g., gemfibrozil): can raise imatinib levels. - Other tyrosine kinase inhibitors: additive toxicity risk, especially hepatic.